- Details
- Roni Haas joins Andrea Miyahira to discuss research on prostate cancer radioresistance, focusing on differences between conventional and hypofractionated radiation therapy approaches. The study reveals that conventional radiation treatment, involving multiple small doses over time, leads to a more aggressive radioresistant phenotype with greater mutations and driver gene dysregulation compared to...
|
- Details
- Felipe Eltit joins Andrea Miyahira to discuss his research on prostate cancer bone metastases, focusing on their structural characteristics and impact on bone health. His study investigates how these metastases, which occur in 90% of advanced prostate cancer patients, generate osteoblastic lesions that paradoxically lead to bone weakness and pain. Using high-resolution imaging techniques, includin...
|
- Details
- Andrea Miyahira interviews Bianca Cali about a Cancer Cell paper examining the role of Coagulation Factor X in prostate cancer treatment resistance. Dr. Cali discusses their discovery that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in tumors produce Factor X (F10), which promotes androgen-independent cell proliferation through PAR2 receptor signaling. The research identifies a...
|
- Details
- Andrea Miyahira interviews Timothy Rebbeck about his research group's Nature Genetics paper examining prostate cancer genetic susceptibility in sub-Saharan Africa. The study analyzes approximately 7,000 individuals across African centers, revealing significant genetic heterogeneity in prostate cancer risk both within Africa and between African and non-African populations. Dr. Rebbeck discusses the...
|
- Details
- Sarah Amend discusses research on polyaneuploid cancer cells (PACCs) and their role in metastasis, published in Molecular Cancer Research. Dr. Amend explains how cancer cells under stress enter an adaptive endocycling state, increasing dramatically in size and genomic content without dividing. The discussion highlights their findings that cells in the PACC state are preferentially found in circula...
|
- Details
- Andrea Miyahira interviews Hala Borno about Trial Library, an innovative platform developed to improve access to clinical trials and increase diversity in trial participation. The technology-enabled service connects community providers with clinical trials while offering comprehensive patient navigation support, addressing social determinants of health and practical barriers to trial participation...
|
- Details
- Samir Zaidi joins Andrea Miyahira to discuss a paper on single-cell analysis of treatment-resistant prostate cancer. Using advanced single-cell technologies, the study reveals significant diversification in gene programs within castrate-resistant prostate cancer, identifying multiple tumor states and transcription factor networks that emerge as resistance mechanisms to androgen receptor signaling...
|
- Details
- Andrea Miyahara speaks with Sheng-Yu Ku about a Journal of Clinical Investigation publication examining the role of Notch signaling in neuroendocrine prostate cancer. The research demonstrates that Notch signaling acts as a tumor suppressor in neuroendocrine prostate cancer by suppressing neuroendocrine differentiation and inducing prostate luminal lineage development. Dr. Ku's work reveals how No...
|
- Details
- Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...
|
- Details
- Raunak Shrestha discusses a published study on chromatin accessibility in advanced prostate cancer. The research, which represents the largest collection of ATAC-seq profiles in metastatic prostate cancer to date, reveals distinct chromatin accessibility patterns across different cancer subtypes. The study identifies 203 transcription factors associated with various metastatic prostate cancer subt...
|
